Pay in 4 interest-free payments of $7.11 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
Realistic Expectations: Maintaining consistent treatment and managing expectations are crucial for achieving optimal results
This personalized approachinformed by your genetics and biomarkersincreases the likelihood of a better treatment fit and reduced side effects
If the Phase 3 trials (TRIUMPH series) read out as expected, MHRA approval is plausible in late 2026 or 2027
While not a direct IBS predictor, it reveals your individual peptide sensitivity profile, allowing your PlexusDx clinician to recommend the safest, most effective medication and dosing strategy for your genetics and medical history
Study #4 This study was also conducted using the TriNetX database
US$ 28.43
US$ 24.65
US$ 25.90
